# WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

> **NCT00275314** · PHASE3 · TERMINATED · sponsor: **University of Pittsburgh** · enrollment: 5 (—)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT00275314
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 5 (—)
- **Why stopped:** Study never started at our site Funding issue
- **Last updated:** 2015-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275314, "WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00275314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*